Repurposing infectious disease vaccines for intratumoral immunotherapy

被引:19
|
作者
Melero, Ignacio [1 ]
Gato, Maria [1 ]
Shekarian, Tala [2 ]
Aznar, Angela [1 ]
Valsesia-Wittmann, Sandrine [2 ]
Caux, Christophe [2 ]
Etxeberrria, Inaki [1 ]
Teijeira, Alvaro [1 ]
Marabelle, Aurelien [3 ]
机构
[1] Ctr Invest Med Aplicada CIMA, Inmunol & Immunotherapy Dept, Avda Pio XII 55, Pamplona 31008, Spain
[2] Univ Lyon, Ctr Rech Cancerol Lyon CRCL, Ctr Lutte Canc Leon Berard, CNRS 5286,INSERM,UMR,U1052, F-69008 Lyon, France
[3] Univ Paris Saclay, INSERM, Drug Dev Dept DITEP, Gustave Roussy,U1015, F-94805 Paris, France
关键词
immunology; virology;
D O I
10.1136/jitc-2019-000443
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Intratumoral delivery of viruses and virus-associated molecular patterns can achieve antitumor effects that are largely mediated by the elicitation or potentiation of immune responses against the malignancy. Attenuated vaccines are approved and marketed as good manufactiring practice (GMP)-manufactured agents whose administration might be able to induce such effects. Recent reports in mouse transplantable tumor models indicate that the rotavirus, influenza and yellow fever vaccines can be especially suitable to elicit powerful antitumor immunity against cancer following intratumoral administration. These results highlight that intratumoral anti-infectious vaccines can turn cold tumors into hot, and underscore the key role played by virus-induced type I interferon pathways to overcome resistance to immune checkpoint-targeted antibodies.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade
    Shekarian, Tala
    Sivado, Eva
    Jallas, Anne-Catherine
    Depil, Stephane
    Kielbassa, Janice
    Janoueix-Lerosey, Isabelle
    Hutter, Gregor
    Goutagny, Nadege
    Bergeron, Christophe
    Viari, Alain
    Valsesia-Wittmann, Sandrine
    Caux, Christophe
    Marabelle, Aurelien
    SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (515)
  • [2] Repurposing the yellow fever vaccine for intratumoral immunotherapy
    Aznar, Maria Angela
    Molina, Carmen
    Teijeira, Alvaro
    Rodriguez, Inmaculada
    Azpilikueta, Arantza
    Garasa, Saray
    Sanchez-Paulete, Alfonso R.
    Cordeiro, Luna
    Etxeberria, Inaki
    Alvarez, Maite
    Rius-Rocabert, Sergio
    Nistal-Villan, Estanislao
    Berraondo, Pedro
    Melero, Ignacio
    EMBO MOLECULAR MEDICINE, 2020, 12 (01)
  • [3] Repurposing the yellow fever vaccine for intratumoral immunotherapy
    Angela Aznar, M.
    Molina, Carmen
    Teijeira, Alvaro
    Azpilikueta, Arantza
    Garasa, Saray
    Sanchez-Paulete, Alfonso R.
    Etxeberria, Inaki
    Alvarez, Maite
    Berraondo, Pedro
    Melero, Ignacio
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Repurposing Infectious Diseases Vaccines Against Cancer
    Vandeborne, Liese
    Pantziarka, Pan
    Van Nuffel, An M. T.
    Bouche, Gauthier
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [5] Repurposing infectious diseases vaccines against cancer.
    Bouche, Gauthier
    Vandeborne, Liese
    Pantziarka, Pan
    Van Nuffel, An M. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] DepoVax™: A Novel Delivery Formulation for Cancer Immunotherapy and Infectious Disease Vaccines
    Stanford, Marianne
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2017, 20 : 16S - 16S
  • [7] Infectious disease vaccines
    Shen, Angela K.
    Cooke, M. Timothy
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (03) : 169 - 170
  • [8] Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics
    Sayour, Elias J.
    Sanchez-Perez, Luis
    Flores, Catherine
    Mitchell, Duane A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [9] VACCINES AND INFECTIOUS-DISEASE
    METZGER, H
    ASKONAS, B
    IMMUNOLOGY TODAY, 1982, 3 (03): : 57 - 59
  • [10] Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN
    Geary, S. M.
    Lemke, C. D.
    Lubaroff, D. M.
    Salem, A. K.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (09) : 1309 - 1317